Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma, Inc. (IMMX)
Company Research
Source: GlobeNewswire
– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch –– Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission – LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch. “In AL Amyloidosis, the immune system produces toxic light chains that clog up the heart, kidney and liver, causing organ failure and death. In our trials, we have seen that one-and-done NXC-201 eliminates the source of these toxic light chains. If approved, NXC-201 would be the first FDA approved treatment for relapsed/refractory AL Amyloidosis,” said Ilya Ra
Show less
Read more
Impact Snapshot
Event Time:
IMMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMX alerts
High impacting Immix Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
IMMX
News
- Immix Biopharma (IMMX) had its price target raised by Mizuho from $14.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Immix Biopharma (IMMX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $23.00 price target on the stock.MarketBeat
- Immix Biopharma (IMMX) had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Immix Biopharma (IMMX) is now covered by Morgan Stanley. They set an "overweight" rating and a $20.00 price target on the stock.MarketBeat
- Immix Biopharma (IMMX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMMX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" MarketBeat
IMMX
Sec Filings
- 3/30/26 - Form 8-K
- 3/27/26 - Form 10-K/A
- 3/25/26 - Form S-8
- IMMX's page on the SEC website